If you are looking up the performance of alna stock, you are likely met with a series of confusing results. Depending on where you look, you might see a stock ticker that appears completely dead, a symbol with a strange "Q" appended to the end, or an active ticker trading on the London Stock Exchange in British pence.
This confusion exists because the ticker ALNA represents two completely different corporate entities. The first is Allena Pharmaceuticals, Inc., a defunct U.S. biotechnology company that formerly traded under the NASDAQ ticker ALNA (and later the OTC ticker ALNAQ) before filing for bankruptcy and undergoing complete liquidation. The second is Alina Holdings PLC, an active investment and property company trading on the London Stock Exchange (LSE) under the ticker ALNA.
To help you untangle this mess, this comprehensive guide will detail the rise, fall, and final bankruptcy liquidation of Allena Pharmaceuticals, explain what happened to its clinical pipeline, and provide an overview of the active UK-listed Alina Holdings PLC for investors who stumbled onto it by accident.
What is ALNA Stock? Clearing Up the Ticker Confusion
When retail investors search for "alna stock," they are often trying to track down the status of their holdings or seeking to understand the sudden disappearance of a biotech penny stock they once followed. To understand the current landscape of the ALNA ticker, it is necessary to divide the term into its two distinct meanings:
Allena Pharmaceuticals, Inc. (Defunct - US): This was a clinical-stage biopharmaceutical company that went public on the NASDAQ in late 2017 under the ticker ALNA. After running out of cash to fund its late-stage clinical trials, the company filed for Chapter 11 bankruptcy in September 2022. It was subsequently delisting from the NASDAQ, briefly traded on the Over-The-Counter (OTC) Pink Sheets as "ALNAQ," and was fully liquidated. Its common stock has been cancelled, meaning it holds a value of exactly zero and no longer trades anywhere.
Alina Holdings PLC (Active - UK): This is a completely unrelated, active investment company traded on the Main Market of the London Stock Exchange under the ticker "ALNA". Originally operating as a Real Estate Investment Trust (REIT) under the name Town Centre Shops, it pivoted in late 2020 to focus on business acquisitions and broader equity investments alongside its residual retail property holdings.
Understanding which "ALNA" you are researching is the first step. For U.S. investors who held shares prior to late 2022, the story is one of bankruptcy and total equity wipeout. For UK and global micro-cap investors, the story is about a small investment trust navigating the post-pandemic real estate market.
The Rise and Fall of Allena Pharmaceuticals (ALNA/ALNAQ)
Allena Pharmaceuticals was founded in 2011 with an ambitious and promising mission: to discover, develop, and commercialize first-in-class, oral biological therapeutics to treat patients with rare and severe metabolic and kidney disorders. Backed by prominent venture capital firms—including Third Rock Ventures, Bessemer Venture Partners, and Frazier Healthcare—the startup raised $15 million in its Series A round.
The Science: GI-Restricted Enzymes
Allena's primary technological edge was its focus on non-absorbed, orally administered enzymes. Traditional protein therapeutics often require intravenous injection and must circulate systematically to be effective, which can lead to off-target toxicities and immune reactions. Allena designed its enzymes to remain entirely within the gastrointestinal (GI) tract. Once ingested, these enzymes would degrade specific toxic metabolites—such as oxalate or uric acid—directly within the gut, preventing them from being absorbed into the bloodstream and reaching the kidneys.
The Clinical Pipeline
Allena's pipeline was centered around two lead candidate drugs:
- Reloxaliase: An investigational, first-in-class oral oxalate-degrading enzyme. It was designed to treat enteric hyperoxaluria (EH), a severe metabolic disorder characterized by high levels of urinary oxalate, which leads to recurrent kidney stones, nephrocalcinosis, and potentially end-stage renal disease (ESRD).
- ALLN-346: A potential first-in-class, orally administered urate-degrading enzyme. It targeted hyperuricemia (excess uric acid in the blood) and gout in patients with advanced chronic kidney disease (CKD). Since the kidneys are responsible for clearing uric acid, patients with stages 2, 3, or 4 CKD frequently suffer from debilitating gout flares and cannot safely take standard systemic gout medications like allopurinol.
Clinical Progress and the FDA Fast Track
For several years, the company made notable clinical progress. In late 2021, Allena announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track Designation to ALLN-346. The company commenced two critical trials: Study 201, a short-term inpatient trial evaluating the safety and efficacy of ALLN-346, and Study 202, a multi-center outpatient study across 23 U.S. sites. Early data from the first cohort of Study 202 demonstrated a statistically significant reduction in serum uric acid compared to the placebo, bringing a wave of optimism to the company and its retail shareholder base.
Downward Spiral: Why Allena's Stock Crashed to Zero
Despite the promising science, Allena Pharmaceuticals fell victim to the classic pitfall of pre-commercial biotechnology companies: the cash burn rate. Developing novel drugs through phase 2 and phase 3 clinical trials is an extraordinarily expensive endeavor, often costing hundreds of millions of dollars before a single dollar of commercial revenue is generated.
The Funding Dilemma and Severe Dilution
As a pre-revenue company, Allena was entirely dependent on external capital markets. When the macroeconomic environment shifted in late 2021 and 2022—marked by rising interest rates, inflation, and a severe downturn in the biotech sector—funding dried up.
To survive, Allena resorted to highly dilutive measures. In May 2022, the company announced a registered direct offering of common stock to raise a meager $2.8 million. This was a clear sign of distress, as it heavily diluted existing shareholders and barely provided enough cash to fund operations for a few weeks. The company also repeatedly scheduled and postponed special shareholder meetings to approve a reverse stock split—a desperate attempt to boost the stock price above the NASDAQ's $1.00 minimum bid requirement to avoid delisting.
Transition to the OTC Markets and the "ALNAQ" Ticker
By summer 2022, the company's financial state was critical. Having failed to secure a strategic merger, partnership, or additional financing, the NASDAQ suspended trading of ALNA stock. The ticker was subsequently moved to the Over-The-Counter (OTC) Markets.
When a company listed on the OTC is undergoing bankruptcy proceedings, the letter "Q" is appended to its ticker symbol. Thus, ALNA became ALNAQ. For a brief period, speculative day traders and retail buyers engaged in volatile trading of ALNAQ, hoping for a meme-stock style recovery. However, the operational reality of the company made a recovery virtually impossible.
The Chapter 11 Bankruptcy and Plan of Liquidation
On September 2, 2022, Allena Pharmaceuticals officially filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the District of Delaware (Case No. 22-10842).
Reorganization vs. Liquidation
While Chapter 11 bankruptcy is traditionally used by companies to restructure their debts, downsize, and emerge as a viable ongoing business, Allena's filing was a vehicle for a controlled wind-down and asset sale. The company appointed Matthew Foster of Sonoran Capital Advisors as Chief Restructuring Officer and engaged SSG Advisors to market and sell its remaining clinical assets and intellectual property.
The Final Blow: The Amended Plan of Liquidation
On May 18, 2023, the Honorable Karen B. Owens of the Delaware Bankruptcy Court confirmed Allena's Amended Plan of Liquidation. The plan established a Liquidation Trust to distribute any remaining funds from asset sales to the company's creditors.
Crucially for equity holders, the bankruptcy court filings explicitly declared that the Plan of Liquidation would result in the complete cancellation and extinguishment of all outstanding shares of common stock. Under the absolute priority rule of U.S. bankruptcy law, creditors must be paid in full before equity holders receive any distribution. Because Allena's liabilities vastly exceeded the value of its liquidated assets, secured lenders and unsecured creditors received only fractional payments on their claims. Retail shareholders who held ALNA or ALNAQ stock lost 100% of their investment, and the shares were formally deleted from brokerage accounts.
Alina Holdings PLC (LSE: ALNA): The Active Investment Trust Alternative
For investors who look up "ALNA stock" today and see an active, trading stock price quoted in British pence (GBX), they are looking at Alina Holdings PLC.
History and Shift in Business Strategy
Alina Holdings PLC is a UK-registered company listed on the Main Market of the London Stock Exchange. Historically, the company operated as a Real Estate Investment Trust (REIT) under the name Town Centre Shops. It managed a portfolio of local retail shopping assets, suburban parades, and neighborhood convenience stores throughout the United Kingdom.
In 2013, the company began a multi-year program to dispose of its physical property assets. After selling the majority of its real estate holdings and withdrawing from the UK REIT tax regime, the company officially rebranded as Alina Holdings PLC and adopted a brand-new investment strategy in September 2020.
The Current Mandate
Alina Holdings' current objective is to identify, acquire, and manage interests in high-potential target businesses capable of delivering long-term capital appreciation and value for its shareholders. It operates in a manner similar to a small-cap closed-end investment trust.
According to its recent financial reports, the company's portfolio is divided into two primary segments:
- Investment Properties: Residual real estate assets in the UK that continue to generate rental income and wait for favorable market conditions to be sold.
- Strategic Equity Investments: Capital deployed into other operating businesses or public equities where the board believes it can influence growth and operational improvements.
Net Asset Value (NAV) and Performance
As of early 2026, Alina Holdings PLC trades at a micro-cap valuation, with a market capitalization of under £3 million. Like many small-cap investment trusts, the stock frequently trades at a substantial discount to its Net Asset Value (NAV). For example, while the estimated NAV per share has hovered around 16.90p, the shares have traded in a 52-week range of roughly 5.90p to 16.00p. This discount reflects the limited liquidity of the stock and the broader macroeconomic pressures facing UK retail real estate and small-cap equities.
Crucial Lessons for Biotech and Micro-cap Investors
The dual stories behind the ALNA ticker offer several vital lessons for retail investors navigating the stock market:
1. The Cash Runway is More Important Than the Science
In early-stage biotechnology investing, a company can have revolutionary science and enthusiastic support from clinical investigators, but if it lacks the capital to complete its trials, the stock is highly vulnerable. Investors must consistently check the "Going Concern" disclosures in SEC filings (specifically Form 10-K and 10-Q) and calculate the cash runway (cash holdings divided by quarterly cash burn rate) before investing.
2. Fast Track Status is Not a Guarantee of Financial Survival
The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions, but it does not come with funding. Retail investors often mistake regulatory milestones, like Fast Track status or successful Phase 1 trials, as a guarantee of commercial success. Without a deep-pocketed pharmaceutical partner, small biotechs remain high-risk plays.
3. Understand the Absolute Priority Rule
When a company enters bankruptcy, many retail traders assume that the stock will eventually recover or that they will receive shares in the restructured company. In reality, under the absolute priority rule, equity holders are the absolute last in line. In a liquidation scenario like Allena's, common stock is canceled, leaving shareholders with nothing but a tax-deductible capital loss.
4. Double-Check Tickers and Exchange Suffixes
Always verify the exchange and country of the ticker you are trading. Buying LSE:ALNA thinking you are buying a recovering U.S. pharmaceutical player (or vice versa) is an easily avoidable mistake. Brokers use suffixes (such as .L for London or .QA for bankrupt OTC) to prevent these errors, but investors must remain vigilant.
Frequently Asked Questions
Is Allena Pharmaceuticals (ALNA stock) still trading?
No. Allena Pharmaceuticals (formerly NASDAQ: ALNA, OTC: ALNAQ) has been fully liquidated following its Chapter 11 bankruptcy. Its outstanding common stock was legally cancelled and extinguished in May 2023. It does not trade on any exchange, and the company no longer exists.
How can I claim a tax write-off for my lost ALNAQ shares?
Because the shares were legally cancelled and deemed worthless under the confirmed bankruptcy liquidation plan, most brokerages will automatically mark the position as having a value of $0.00 and remove it. You can typically claim this as a realized capital loss on your taxes. It is highly recommended to consult a tax professional and review your annual Form 1099-B to ensure the loss is correctly reported.
Who owns Allena's clinical drug candidates like ALLN-346 and Reloxaliase now?
During the Chapter 11 bankruptcy process, Allena's intellectual property, clinical data, and drug development assets were put up for sale by SSG Advisors. These assets were sold to third-party buyers to raise funds to pay off secured creditors. Any future development of ALLN-346 or Reloxaliase would be conducted by these purchasing entities, completely independent of the original Allena Pharmaceuticals corporate structure.
Why does Alina Holdings share the same ticker (ALNA)?
Ticker symbols are not globally unique; they are only unique within a specific stock exchange. Allena Pharmaceuticals was listed on the NASDAQ in the United States under the ticker ALNA. Alina Holdings PLC is listed on the London Stock Exchange (LSE) in the United Kingdom under the ticker ALNA. Because they trade on different international exchanges, they are permitted to use the same four-letter ticker.
Is Alina Holdings PLC a good investment?
Alina Holdings PLC (LSE: ALNA) is a highly illiquid micro-cap investment company. While it trades at a discount to its Net Asset Value (NAV), micro-cap stocks carry extreme volatility, wide bid-ask spreads, and unique operational risks. Investors should carefully review its annual financial reports, the composition of its remaining real estate holdings, and its management team's track record before committing capital.
Conclusion
The keyword "alna stock" serves as a tale of two entirely different market pathways. For those following the U.S. markets, the ticker represents the unfortunate demise of Allena Pharmaceuticals, a promising biotech firm whose oral enzyme technology was ultimately starved of the immense capital required for clinical commercialization. For those looking at the UK markets, it represents Alina Holdings PLC, a small-cap investment vehicle undergoing its own long-term structural pivot from brick-and-mortar retail real estate to diversified business acquisitions.
By understanding the bankruptcy mechanisms that dissolved Allena and the distinct corporate identity of Alina Holdings, investors can clean up their portfolios, accurately report tax losses, and avoid costly ticker confusion in the future.
